AHL Partners LLP boosted its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 11.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,874 shares of the medical instruments supplier’s stock after acquiring an additional 5,613 shares during the quarter. AHL Partners LLP owned 0.15% of AngioDynamics worth $890,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Bank of New York Mellon Corp raised its holdings in AngioDynamics by 4.5% during the first quarter. Bank of New York Mellon Corp now owns 495,099 shares of the medical instruments supplier’s stock worth $8,591,000 after purchasing an additional 21,277 shares in the last quarter. Comerica Bank raised its holdings in AngioDynamics by 5.8% during the first quarter. Comerica Bank now owns 35,175 shares of the medical instruments supplier’s stock worth $537,000 after purchasing an additional 1,932 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new stake in AngioDynamics during the first quarter worth approximately $191,000. Texas Permanent School Fund raised its holdings in AngioDynamics by 0.6% during the first quarter. Texas Permanent School Fund now owns 23,129 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 145 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its holdings in AngioDynamics by 25.8% during the first quarter. Parametric Portfolio Associates LLC now owns 101,772 shares of the medical instruments supplier’s stock worth $1,766,000 after purchasing an additional 20,901 shares in the last quarter. 95.42% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO James C. Clemmer purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were acquired at an average cost of $15.64 per share, with a total value of $312,800.00. Following the transaction, the chief executive officer now owns 86,683 shares in the company, valued at approximately $1,355,722.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO James C. Clemmer purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The shares were purchased at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the completion of the transaction, the chief executive officer now owns 86,683 shares in the company, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 25,316 shares of company stock valued at $396,806. Company insiders own 1.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “AHL Partners LLP Has $890,000 Position in AngioDynamics, Inc. (ANGO)” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.watchlistnews.com/ahl-partners-llp-has-890000-position-in-angiodynamics-inc-ango/1638284.html.

A number of analysts have weighed in on ANGO shares. Cantor Fitzgerald raised their price objective on shares of AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, July 4th. Canaccord Genuity reissued a “hold” rating and set a $17.00 price objective on shares of AngioDynamics in a report on Tuesday, July 18th. Barclays PLC cut their price objective on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 19th. Zacks Investment Research cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a report on Thursday, July 20th. Finally, BidaskClub cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. AngioDynamics currently has a consensus rating of “Hold” and an average price target of $18.60.

Shares of AngioDynamics, Inc. (NASDAQ ANGO) opened at 17.22 on Wednesday. The firm has a market cap of $632.23 million, a PE ratio of 173.94 and a beta of 1.12. AngioDynamics, Inc. has a 12-month low of $14.80 and a 12-month high of $18.85. The firm’s 50-day moving average is $17.36 and its 200-day moving average is $16.36.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The business had revenue of $85.40 million for the quarter, compared to analysts’ expectations of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share. Equities analysts expect that AngioDynamics, Inc. will post $0.66 earnings per share for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.